Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

TetraPhase raises $45mm in Series C round

Executive Summary

Antibiotics developer TetraPhase Pharmaceuticals Inc. raised $45mm in its Series C financing led by first-time backer Excel Venture Management, which adds a board member. Returning shareholders CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners, and Skyline Ventures also participated along with eight undisclosed investors. The funds will support ongoing development of its candidates--TP434, a broad-spectrum IV antibiotic set to enter Phase II this year; preclinical TP2758 for complicated urinary tract infections; and preclinical TP834 for community-acquired bacterial pneumonia.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies